NEW YORK (GenomeWeb News) – Cepheid reported after the market closed on Thursday that its third quarter revenues increased 24 percent year over year.

The Sunnyvale, Calif.-based molecular diagnostics firm reported total revenues of $100.1 million for the three months ended Sept. 30, compared to $80.5 million for the third quarter of 2012. It exceeded the consensus analysts' estimate of $93.9 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.